Emavusertib is a targeted cancer therapeutic agent primarily investigated for its use in treating solid tumors, especially those driven by mutations in the CSF1R (colony-stimulating factor 1 receptor) pathway. It functions by inhibiting specific kinases involved in tumor cell proliferation and survival, particularly in cancers with aberrant macrophage signaling. Its application is most prominent in clinical trials for advanced or metastatic cancers where conventional therapies have failed. Emavusertib has shown potential in combination with immune checkpoint inhibitors, enhancing anti-tumor immune responses by modifying the tumor microenvironment. It is being evaluated in patients with tenosynovial giant cell tumor (TGCT) and other CSF1R-dependent neoplasms, offering a promising option for rare and difficult-to-treat cancers.